Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00129753|
Recruitment Status : Withdrawn (Terminated due to slow accrual.)
First Posted : August 12, 2005
Last Update Posted : November 8, 2018
To determine the safety and efficacy of Campath-1H (Alemtuzumab) in patients with relapsed and resistant classical Hodgkin's lymphoma.
- To determine the duration of response and time to progression after Campath-1H therapy in this patient population.
- To determine the effect of Campath-1H on serum IL-6, IL-10, and IL-13 levels in patients with relapsed and resistant classical Hodgkin's lymphoma.
|Condition or disease||Intervention/treatment||Phase|
|Hodgkin's Disease Lymphoma||Drug: Alemtuzumab (Campath-1H)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease|
|Actual Study Start Date :||June 22, 2005|
|Actual Primary Completion Date :||September 5, 2006|
|Actual Study Completion Date :||September 5, 2006|
Drug: Alemtuzumab (Campath-1H)
Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
- Response Rate [ Time Frame: 1 Year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00129753
|Principal Investigator:||Anas Younes, M.D.||UT MD Anderson Cancer Center|